Prostate cancer recurrent
Information
- Disease name
- Prostate cancer recurrent
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03444844 | Active, not recruiting | Phase 1/Phase 2 | Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer | May 10, 2018 | July 2022 |
| NCT04114825 | Active, not recruiting | Phase 2 | Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer | November 19, 2019 | November 2022 |
| NCT04011410 | Active, not recruiting | Phase 2 | Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer | December 3, 2019 | November 18, 2026 |
| NCT04742361 | Active, not recruiting | Phase 3 | Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer | September 8, 2021 | June 2024 |
| NCT02560181 | Active, not recruiting | N/A | Pilot Study of Whole Gland Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer | August 2014 | August 30, 2024 |
| NCT02562131 | Active, not recruiting | PET-MR-PSA Prostate Cancer Recidive Study | September 2015 | December 2027 | |
| NCT02974075 | Active, not recruiting | N/A | Salvage Lymph Node Dissection in Prostate Cancer Patients With Recurrence After Radical Prostatectomy | August 2016 | November 2024 |
| NCT04452136 | Approved for marketing | Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer | |||
| NCT04428203 | Completed | Phase 1 | Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer | August 3, 2020 | August 20, 2021 |
| NCT03443609 | Completed | N/A | Study of 68Ga-HBED-PSMA PET/CT and Conventional Imaging in Occult Biological Relapse Prostate Cancer | March 31, 2017 | September 29, 2019 |
| NCT03329742 | Completed | N/A | Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer | December 19, 2017 | May 5, 2020 |
| NCT02176161 | Completed | Phase 2 | Metformin Prostate Cancer Adjuvant Trial | June 2014 | July 21, 2021 |
| NCT03604211 | Completed | SBRT for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience | January 2010 | July 2018 | |
| NCT03739684 | Completed | Phase 3 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer | November 27, 2018 | August 29, 2019 |
| NCT04324983 | Completed | N/A | Identification of Predictive Biomarkers | March 1, 2020 | April 5, 2023 |
| NCT03396874 | Completed | Phase 2 | Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence | February 9, 2018 | August 9, 2022 |
| NCT04102553 | Completed | Phase 3 | F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence | March 6, 2019 | March 19, 2021 |
| NCT01857037 | Completed | N/A | Post-radiation Prostate Cancer Local Recurrences: Detection With Histoscanning™ and MRI | May 2011 | August 2014 |
| NCT04134130 | Completed | N/A | The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer | September 16, 2019 | December 31, 2019 |
| NCT04644822 | Completed | Phase 3 | Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer. | December 21, 2020 | January 8, 2024 |
| NCT05002465 | No longer available | Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer | |||
| NCT04312191 | Not yet recruiting | N/A | Using Meditation for Oncology Anxiety | January 31, 2024 | February 1, 2025 |
| NCT06220188 | Recruiting | Phase 2 | PSMA-RLT in Biochemically Recurrent PCa | January 15, 2024 | January 2027 |
| NCT04641078 | Recruiting | Phase 2 | Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer | February 12, 2021 | February 12, 2026 |
| NCT05022914 | Recruiting | PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE | January 19, 2021 | January 19, 2027 | |
| NCT05036226 | Recruiting | Phase 1/Phase 2 | COAST Therapy in Advanced Solid Tumors and Prostate Cancer | March 3, 2022 | October 15, 2025 |
| NCT05352178 | Recruiting | Phase 3 | Metastasis-directed Therapy for Oligorecurrent Prostate Cancer | April 20, 2022 | April 25, 2032 |
| NCT05384002 | Recruiting | An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum | February 24, 2021 | September 30, 2024 | |
| NCT05646550 | Recruiting | Phase 1 | Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer | November 11, 2022 | December 2026 |
| NCT05848011 | Recruiting | Phase 2 | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer | September 28, 2023 | September 2027 |
| NCT01512472 | Terminated | Phase 4 | Firmagon (Degarelix) Intermittent Therapy | January 2012 | January 2018 |
| NCT04239742 | Unknown status | N/A | F18-PSMA-1007 PET for Early Biochemical Recurrence of Prostate Cancer | January 2, 2020 | January 2023 |
| NCT04686188 | Unknown status | Exploring the Mechanisms and Dynamics of Clonal Evolution Leading to Recurrence in Prostate Cancer | November 26, 2020 | September 1, 2022 | |
| NCT04734184 | Unknown status | Phase 3 | A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer | July 7, 2020 | February 2022 |
| NCT03507595 | Unknown status | Evaluation of the Metastasis and Recurrence of Prostate Cancer | September 1, 2017 | December 31, 2019 | |
| NCT04876755 | Unknown status | Phase 2 | MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer | May 30, 2021 | February 2023 |
| NCT01938339 | Unknown status | N/A | Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer | May 2012 | December 2014 |
| NCT04983628 | Unknown status | Molecular Profiling in Prostate Cancer | October 1, 2020 | August 1, 2023 |